Pulmonx Corporation
We are a global leader in interventional pulmonology, planning tools, and treatments for obstructive lung disease.
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is the maker of the Zephyr® Endobronchial Valve. The Zephyr Valve was granted breakthrough status and approved by the FDA in June 2018 and obtained CE mark in 2003. According to the FDA it “represents a breakthrough technology as the device offers bronchoscopic lung volume reduction without surgery and its associated risks. This device offers a significant, clinically meaningful advantage over the current standard of care and therefore, its availability is also in the best interest of patients.”¹
Patients in Europe, the United States, Australia, Asia, Latin America, and other countries worldwide may benefit from Zephyr Endobronchial Valves.
Mission
To be the global leader and trusted partner in assessment and treatment of severe lung disease by innovating and commercializing evidence-based solutions to improve patients' breathing and quality of life.
Values
Patient Focus
We put the best interest of our patients at the center of our decisions, and seek to delight our customers as we partner to serve patients.
Innovation
We adapt quickly, and continuously seek new ways to create value for our customers, employees, and shareholders.
Science
We take a data-driven approach to decision making, clinical strategy, and commercial execution.
Global Collaboration
We seek diverse perspectives and teams that work respectfully across geographies and functions to bring our innovations to patients around the world.
Accountability
We deliver on our commitments with integrity, transparency, sound judgement, and a sense of urgency.
Zephyr® Valves
We have the opportunity to improve the lives of people suffering from severe COPD/emphysema all around the world. Our team understands this sense of responsibility and feels passionate about helping these patients breathe easier.
The Zephyr Endobronchial Valve is an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema.
Contact us
Europe, Middle East, and Africa Office
Pulmonx International Sarl Rue de la Treille 4, 2000 Neuchâtel, Switzerland
1. Food and Drug Admistration (FDA), Summary of Safety and Effectiveness document for the Pulmonx Zephyr Endobronchial Valve System, June 29, 2018 (https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180002B.pdf)